The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Drugs for Central Nervous System Market Research Report 2024
Synopsis
The central nervous system (CNS) is the part of thenervous system consisting of the brain and spinal cord. In this report, we study the drugs for central nervous system disease.
The global Drugs for Central Nervous System market was valued at US$ 115260 million in 2023 and is anticipated to reach US$ 186780 million by 2030, witnessing a CAGR of 7.5% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Drugs for Central Nervous System, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Central Nervous System.
Report Scope
The Drugs for Central Nervous System market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Drugs for Central Nervous System market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for Central Nervous System manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Biogen
Pfizer
Teva
Novartis
Johnson & Johnson
EliLilly
Otsuka
Merck
AstraZeneca
Novartis
Takeda
Segment by Type
OTC
Rx Drugs
Segment by Application
Hospital
Retail Pharmacy
Consumption by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Drugs for Central Nervous System manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Drugs for Central Nervous System in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The central nervous system (CNS) is the part of thenervous system consisting of the brain and spinal cord. In this report, we study the drugs for central nervous system disease.
The global Drugs for Central Nervous System market was valued at US$ 115260 million in 2023 and is anticipated to reach US$ 186780 million by 2030, witnessing a CAGR of 7.5% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Drugs for Central Nervous System, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Central Nervous System.
Report Scope
The Drugs for Central Nervous System market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Drugs for Central Nervous System market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for Central Nervous System manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Biogen
Pfizer
Teva
Novartis
Johnson & Johnson
EliLilly
Otsuka
Merck
AstraZeneca
Novartis
Takeda
Segment by Type
OTC
Rx Drugs
Segment by Application
Hospital
Retail Pharmacy
Consumption by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Drugs for Central Nervous System manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Drugs for Central Nervous System in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Drugs for Central Nervous System Market Overview
1.1 Product Overview and Scope of Drugs for Central Nervous System
1.2 Drugs for Central Nervous System Segment by Type
1.2.1 Global Drugs for Central Nervous System Market Value Comparison by Type (2024-2030)
1.2.2 OTC
1.2.3 Rx Drugs
1.3 Drugs for Central Nervous System Segment by Application
1.3.1 Global Drugs for Central Nervous System Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.4 Global Drugs for Central Nervous System Market Size Estimates and Forecasts
1.4.1 Global Drugs for Central Nervous System Revenue 2019-2030
1.4.2 Global Drugs for Central Nervous System Sales 2019-2030
1.4.3 Global Drugs for Central Nervous System Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Drugs for Central Nervous System Market Competition by Manufacturers
2.1 Global Drugs for Central Nervous System Sales Market Share by Manufacturers (2019-2024)
2.2 Global Drugs for Central Nervous System Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Drugs for Central Nervous System Average Price by Manufacturers (2019-2024)
2.4 Global Drugs for Central Nervous System Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Drugs for Central Nervous System, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Drugs for Central Nervous System, Product Type & Application
2.7 Drugs for Central Nervous System Market Competitive Situation and Trends
2.7.1 Drugs for Central Nervous System Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Drugs for Central Nervous System Players Market Share by Revenue
2.7.3 Global Drugs for Central Nervous System Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Drugs for Central Nervous System Retrospective Market Scenario by Region
3.1 Global Drugs for Central Nervous System Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Drugs for Central Nervous System Global Drugs for Central Nervous System Sales by Region: 2019-2030
3.2.1 Global Drugs for Central Nervous System Sales by Region: 2019-2024
3.2.2 Global Drugs for Central Nervous System Sales by Region: 2025-2030
3.3 Global Drugs for Central Nervous System Global Drugs for Central Nervous System Revenue by Region: 2019-2030
3.3.1 Global Drugs for Central Nervous System Revenue by Region: 2019-2024
3.3.2 Global Drugs for Central Nervous System Revenue by Region: 2025-2030
3.4 North America Drugs for Central Nervous System Market Facts & Figures by Country
3.4.1 North America Drugs for Central Nervous System Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Drugs for Central Nervous System Sales by Country (2019-2030)
3.4.3 North America Drugs for Central Nervous System Revenue by Country (2019-2030)
3.4.4 the United States
3.4.5 Canada
3.5 Europe Drugs for Central Nervous System Market Facts & Figures by Country
3.5.1 Europe Drugs for Central Nervous System Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Drugs for Central Nervous System Sales by Country (2019-2030)
3.5.3 Europe Drugs for Central Nervous System Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 UK
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Drugs for Central Nervous System Market Facts & Figures by Country
3.6.1 Asia Pacific Drugs for Central Nervous System Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Drugs for Central Nervous System Sales by Country (2019-2030)
3.6.3 Asia Pacific Drugs for Central Nervous System Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Drugs for Central Nervous System Market Facts & Figures by Country
3.7.1 Latin America Drugs for Central Nervous System Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Drugs for Central Nervous System Sales by Country (2019-2030)
3.7.3 Latin America Drugs for Central Nervous System Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Drugs for Central Nervous System Market Facts & Figures by Country
3.8.1 Middle East and Africa Drugs for Central Nervous System Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Drugs for Central Nervous System Sales by Country (2019-2030)
3.8.3 Middle East and Africa Drugs for Central Nervous System Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Drugs for Central Nervous System Sales by Type (2019-2030)
4.1.1 Global Drugs for Central Nervous System Sales by Type (2019-2024)
4.1.2 Global Drugs for Central Nervous System Sales by Type (2025-2030)
4.1.3 Global Drugs for Central Nervous System Sales Market Share by Type (2019-2030)
4.2 Global Drugs for Central Nervous System Revenue by Type (2019-2030)
4.2.1 Global Drugs for Central Nervous System Revenue by Type (2019-2024)
4.2.2 Global Drugs for Central Nervous System Revenue by Type (2025-2030)
4.2.3 Global Drugs for Central Nervous System Revenue Market Share by Type (2019-2030)
4.3 Global Drugs for Central Nervous System Price by Type (2019-2030)
5 Segment by Application
5.1 Global Drugs for Central Nervous System Sales by Application (2019-2030)
5.1.1 Global Drugs for Central Nervous System Sales by Application (2019-2024)
5.1.2 Global Drugs for Central Nervous System Sales by Application (2025-2030)
5.1.3 Global Drugs for Central Nervous System Sales Market Share by Application (2019-2030)
5.2 Global Drugs for Central Nervous System Revenue by Application (2019-2030)
5.2.1 Global Drugs for Central Nervous System Revenue by Application (2019-2024)
5.2.2 Global Drugs for Central Nervous System Revenue by Application (2025-2030)
5.2.3 Global Drugs for Central Nervous System Revenue Market Share by Application (2019-2030)
5.3 Global Drugs for Central Nervous System Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Biogen
6.1.1 Biogen Corporation Information
6.1.2 Biogen Description and Business Overview
6.1.3 Biogen Drugs for Central Nervous System Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Biogen Drugs for Central Nervous System Product Portfolio
6.1.5 Biogen Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Corporation Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Drugs for Central Nervous System Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Pfizer Drugs for Central Nervous System Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Teva
6.3.1 Teva Corporation Information
6.3.2 Teva Description and Business Overview
6.3.3 Teva Drugs for Central Nervous System Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Teva Drugs for Central Nervous System Product Portfolio
6.3.5 Teva Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Corporation Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Drugs for Central Nervous System Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novartis Drugs for Central Nervous System Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Johnson & Johnson
6.5.1 Johnson & Johnson Corporation Information
6.5.2 Johnson & Johnson Description and Business Overview
6.5.3 Johnson & Johnson Drugs for Central Nervous System Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Johnson & Johnson Drugs for Central Nervous System Product Portfolio
6.5.5 Johnson & Johnson Recent Developments/Updates
6.6 EliLilly
6.6.1 EliLilly Corporation Information
6.6.2 EliLilly Description and Business Overview
6.6.3 EliLilly Drugs for Central Nervous System Sales, Revenue and Gross Margin (2019-2024)
6.6.4 EliLilly Drugs for Central Nervous System Product Portfolio
6.6.5 EliLilly Recent Developments/Updates
6.7 Otsuka
6.6.1 Otsuka Corporation Information
6.6.2 Otsuka Description and Business Overview
6.6.3 Otsuka Drugs for Central Nervous System Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Otsuka Drugs for Central Nervous System Product Portfolio
6.7.5 Otsuka Recent Developments/Updates
6.8 Merck
6.8.1 Merck Corporation Information
6.8.2 Merck Description and Business Overview
6.8.3 Merck Drugs for Central Nervous System Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Merck Drugs for Central Nervous System Product Portfolio
6.8.5 Merck Recent Developments/Updates
6.9 AstraZeneca
6.9.1 AstraZeneca Corporation Information
6.9.2 AstraZeneca Description and Business Overview
6.9.3 AstraZeneca Drugs for Central Nervous System Sales, Revenue and Gross Margin (2019-2024)
6.9.4 AstraZeneca Drugs for Central Nervous System Product Portfolio
6.9.5 AstraZeneca Recent Developments/Updates
6.10 Novartis
6.10.1 Novartis Corporation Information
6.10.2 Novartis Description and Business Overview
6.10.3 Novartis Drugs for Central Nervous System Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Novartis Drugs for Central Nervous System Product Portfolio
6.10.5 Novartis Recent Developments/Updates
6.11 Takeda
6.11.1 Takeda Corporation Information
6.11.2 Takeda Drugs for Central Nervous System Description and Business Overview
6.11.3 Takeda Drugs for Central Nervous System Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Takeda Drugs for Central Nervous System Product Portfolio
6.11.5 Takeda Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Drugs for Central Nervous System Industry Chain Analysis
7.2 Drugs for Central Nervous System Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Drugs for Central Nervous System Production Mode & Process
7.4 Drugs for Central Nervous System Sales and Marketing
7.4.1 Drugs for Central Nervous System Sales Channels
7.4.2 Drugs for Central Nervous System Distributors
7.5 Drugs for Central Nervous System Customers
8 Drugs for Central Nervous System Market Dynamics
8.1 Drugs for Central Nervous System Industry Trends
8.2 Drugs for Central Nervous System Market Drivers
8.3 Drugs for Central Nervous System Market Challenges
8.4 Drugs for Central Nervous System Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
